We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 366

Will You, Won't You Join The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • February 21 2017

In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has


Federal Circuit Finds "Consisting Of" Requires Reversing Infringement Of Shire Lialda Patent
  • Foley & Lardner LLP
  • USA
  • February 14 2017

The Federal Circuit focused on the “consisting of” language in the claims at issue when it reversed the district court’s finding that Watson’s ANDA


Interference statute does not require diligence for re-presenting claims
  • Foley & Lardner LLP
  • USA
  • December 10 2015

In In re: Commonwealth Scientific & Industrial Research Organisation, the Federal Circuit held that pre-AIA 35 USC 135(b)(1) does not embody a


Court Rejects Theory Of Derivation Based On FDA Requirement
  • Foley & Lardner LLP
  • USA
  • February 7 2017

The Federal Circuit decision in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC may be more interesting for what Mylan argued than for


PTAB Holds Oral Hearings In Tecfidera Patent IPR and Interference
  • Foley & Lardner LLP
  • USA
  • December 6 2016

On November 30, 2016, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the


Amgen And Sandoz Do The Biosimilar Patent Dance Over Neulasta
  • Foley & Lardner LLP
  • USA
  • May 17 2016

Amgen Inc. has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by


PTAB refuses to sanction Kyle Bass
  • Foley & Lardner LLP
  • USA
  • September 28 2015

Many pharmaceutical companies have complained about the IPR petitions filed by Kyle Bass and the Coalition for Affordable Drugs against Orange


Federal Circuit upholds Patent Term Adjustment deduction for IDS filed after Restriction Requirement
  • Foley & Lardner LLP
  • USA
  • March 2 2015

In Gilead Sciences, Inc. v. Lee, the Federal Circuit upheld the USPTO's interpretation of the Patent Term Adjustment (PTA) statute as permitting the


Simultaneous invention as secondary evidence of obviousness
  • Foley & Lardner LLP
  • USA
  • July 21 2015

I do not usually write about non-precedential Federal Circuit decisions, but I could not let the discussion of “simultaneous invention” in Columbia


Federal Circuit upholds broadest reasonable interpretation in inter partes review
  • Foley & Lardner LLP
  • USA
  • July 12 2015

A divided Federal Circuit denied the petition for rehearing en banc that would have required the court to revisit its decision in In re Cuozzo Speed